Novel therapeutics in myocardial infarction: targeting microvascular dysfunction and reperfusion injury

被引：82

作者：

Fordyce, Christopher B. ^{[1
]}

Gersh, Bernard J. ^{[2
]}

Stone, Gregg W. ^{[3
,4
]}

Granger, Christopher B. ^{[1
]}

机构：

[1] Duke Clin Res Inst, Durham, NC 27705 USA

[2] Mayo Clin, Coll Med, Div Cardiovasc Med, Rochester, MN USA

[3] Columbia Univ, Med Ctr, New York Presbyterian Hosp, New York, NY USA

[4] Cardiovasc Res Fdn, New York, NY USA

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 2015年 / 36卷 / 09期

关键词：

myocardial infarction; reperfusion injury; coronary microcirculation; novel therapeutics; PERCUTANEOUS CORONARY INTERVENTION; NO-REFLOW PHENOMENON; TO-BALLOON TIME; DOSE INTRACORONARY ADENOSINE; RANDOMIZED CONTROLLED-TRIAL; GLUCOSE-INSULIN-POTASSIUM; IMPROVES CARDIAC-FUNCTION; PLACEBO-CONTROLLED TRIAL; THROMBUS ASPIRATION; PRIMARY ANGIOPLASTY;

D O I：

10.1016/j.tips.2015.06.004

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Despite the large number of novel therapies under basic scientific investigation, the translation of cardioprotective strategies targeting repel-fusion injury to improve patient outcomes following percutaneous coronary intervention (PCI) for myocardial infarction (MI) has been disappointing. The varying susceptibility of an individual to reperfusion injury, as well as the narrow window of opportunity in which to intervene, adds significant complexity. Here, we discuss the unmet need and challenges of translating cardioprotective strategies into clinical practice, review the pathophysiology of microvascular dysfunction and lethal reperfusion as they relate to promising novel therapeutics, and evaluate recent and ongoing clinical trials in the field.

引用

页码：605 / 616

页数：12

共 137 条

[1]

American College of Emergency PhysiciansSociety for Cardiovascular Angiography and InterventionsO'Gara PT, 2013, J AM COLL CARDIOL, V61, P78

[2]

[Anonymous], EUR SOC CARD SCI SES

[3]

[Anonymous], AM COLL CARD SCI SES

[4]

[Anonymous], CATHETER CARDIOVASC

[5]

[Anonymous], 2014, CIRCULATION, DOI DOI 10.1161/01.cir.0000441139.02102.80

[6]

[Anonymous], AM COLL CARD SCI SES

[7]

[Anonymous], J CARDIOVASC PHARM T

[8]

Argaud Laurent, 2005, J Mol Cell Cardiol, V38, P367, DOI 10.1016/j.yjmcc.2004.12.001

[9]

Armstrong PW, 2007, JAMA-J AM MED ASSOC, V297, P43

[10]

Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results [J].

Atar, Dan ;

Arheden, Hakan ;

Berdeaux, Alain ;

Bonnet, Jean-Louis ;

Carlsson, Marcus ;

Clemmensen, Peter ;

Cuvier, Valerie ;

Danchin, Nicolas ;

Dubois-Rande, Jean-Luc ;

Engblom, Henrik ;

Erlinge, David ;

Firat, Hueseyin ;

Halvorsen, Sigrun ;

Hansen, Henrik Steen ;

Hauke, Wilfried ;

Heiberg, Einar ;

Koul, Sasha ;

Larsen, Alf-Inge ;

Le Corvoisier, Philippe ;

Nordrehaug, Jan Erik ;

Paganelli, Franck ;

Pruss, Rebecca M. ;

Rousseau, Helene ;

Schaller, Sophie ;

Sonou, Giles ;

Tuseth, Vegard ;

Veys, Julien ;

Vicaut, Eric ;

Jensen, Svend Eggert .

EUROPEAN HEART JOURNAL, 2015, 36 (02) :112-119

← 1 2 3 4 5 6 7 8 9 10 →